公开(公告)号：US20230066771A1

公开(公告)日：2023-03-02

申请号：US17443264

申请日：2021-07-23

Applicant: AbbVie Inc.

Inventor： Maria A. Argiriadi ,  Eric C. Breinlinger ,  Kevin P. Cusack ,  Adrian D. Hobson ,  Dominique Potin ,  Martine Barth ,  Jerome Amaudrut ,  Olivia Poupardin ,  Laurent Mounier ,  Michael E. Kort

IPC: C07D209/08 ,  C07D401/10 ,  C07D403/10 ,  C07D401/14 ,  C07D405/12 ,  C07D401/06 ,  C07D491/107 ,  C07D405/14 ,  C07D235/06 ,  C07D471/04 ,  C07D487/04 ,  C07D231/56 ,  C07D235/16 ,  C07D405/10 ,  C07D491/10 ,  C07D209/14 ,  C07D209/18

Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.

公开(公告)号：US10508113B2

公开(公告)日：2019-12-17

申请号：US16299485

申请日：2019-03-12

Applicant: AbbVie Inc.

Inventor： Maria A. Argiriadi ,  Eric C. Breinlinger ,  Ellen Yulin Tsai Chien ,  Marlon D. Cowart ,  Kristine E. Frank ,  Michael M. Friedman ,  David J. Hardee ,  J. Martin Herold ,  Huaqing Liu ,  Wei Qiu ,  Marc J. Scanio ,  Michael R. Schrimpf ,  Thomas R. Vargo ,  Stacy A. Van Epps ,  Matthew P. Webster ,  Andrew J. Little ,  Matthew H. Katcher

IPC: C07D405/14 ,  C07D471/04

Abstract: Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a, R4b, X1, X2, X3, X4, X5, nad n are as defined herein, pharmaeceutical compositions 2C X5, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use.

公开(公告)号：US10266532B2

公开(公告)日：2019-04-23

申请号：US15829243

申请日：2017-12-01

Applicant: AbbVie Inc.

Inventor： Eric C. Breinlinger ,  Phil B. Cox ,  Justin D. Dietrich ,  Kristine E. Frank ,  Michael M. Friedman ,  Huan-Qui Li ,  Kenton L. Longenecker ,  Augustine T. Osuma ,  Ann Marie Rowley ,  Anil Vasudevan ,  Noel S. Wilson ,  Jerome Daanen ,  Stevan Djuric ,  Amanda W. Dombrowski ,  Arthur Gomtsyan ,  Robert Schmidt

IPC: C07D521/00 ,  C07D471/04 ,  C07D471/14 ,  C07D487/04 ,  C07D498/04 ,  C07D498/14 ,  C07D498/18 ,  C07D498/20 ,  C07D498/22 ,  C07D519/00 ,  C07D471/18 ,  C07D491/147 ,  C07D491/22

Abstract: The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.

公开(公告)号：US20180179198A1

公开(公告)日：2018-06-28

申请号：US15829243

申请日：2017-12-01

Applicant: AbbVie Inc.

Inventor： Eric C. Breinlinger ,  Phil B. Cox ,  Justin D. Dietrich ,  Kristine E. Frank ,  Michael M. Friedman ,  Huan-Qui Li ,  Kenton L. Longenecker ,  Augustine T. Osuma ,  Ann Marie Rowley ,  Anil Vasudevan ,  Noel S. Wilson

IPC: C07D471/04 ,  C07D491/147 ,  C07D498/22 ,  C07D487/04 ,  C07D491/22 ,  C07D498/18 ,  C07D471/14 ,  C07D498/04 ,  C07D498/14 ,  C07D498/20 ,  C07D519/00 ,  C07D471/18

CPC classification number: C07D471/04 ,  C07D471/14 ,  C07D471/18 ,  C07D487/04 ,  C07D491/147 ,  C07D491/22 ,  C07D498/04 ,  C07D498/14 ,  C07D498/18 ,  C07D498/20 ,  C07D498/22 ,  C07D519/00

Abstract: The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.

公开(公告)号：US20150297596A1

公开(公告)日：2015-10-22

申请号：US14696680

申请日：2015-04-27

Applicant: ABBVIE INC.

Inventor： David J. Calderwood ,  Eric C. Breinlinger ,  Steven L. Swann ,  Subhendu Mukherjee ,  Venkata Srikanth Chitty ,  Siva Sanjeeva Rao Thunuguntla ,  Subramanya Seetharama Shastry Hosahalli

IPC: A61K31/506 ,  A61K31/541 ,  A61K31/5377

CPC classification number: A61K31/506 ,  A61K31/5377 ,  A61K31/541 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  Y02A50/401 ,  Y02A50/463 ,  Y02A50/481

Abstract: The present invention provides compound of Formula (I) biologically active metabolites, pro-drugs, isomers, stereoisomers, solvates, hydrates and pharmaceutically acceptable salts thereof wherein the variables are defined herein. The compounds of the invention are useful for treating immunological conditions.

Abstract translation: 本发明提供式（I）化合物的生物活性代谢物，前药，异构体，立体异构体，溶剂合物，水合物及其药学上可接受的盐，其中变量在本文中定义。 本发明的化合物可用于治疗免疫学病症。